Affiliation:
1. Narnarayan Shastri Institute of Technology, Gujarat, India
2. Sterling Hospital, Ahmedabad, Gujarat, India
Abstract
Cardiac dysregulation, specifically perturbations in heart rate constitutes a pivotal factor influencing the morbidity and mortality associated with diverse pathological conditions including angina (chronic/stable), acute coronary syndrome, heart failure, renal failure, respiratory distress, chronic obstructive pulmonary disease, multiorgan dysfunction syndrome, mitral valve prolapse, and mitral stenosis. The pharmacological apparatus for heart rate control refined over decades encompasses various classes of agents each adhering to specific protocols. Among these Ivabradine has garnered attention as a non-inferior alternative to extant heart rate-reducing medications providing a subtle approach to cardiovascular therapeutics.
Publisher
IP Innovative Publication Pvt Ltd
Reference16 articles.
1. Ide T, Ohtani K, Higo T, Tanaka M, Kawasaki Y, Tsutsui H, Ivabradine for the treatment of cardiovascular diseases.Circ J Internet 2019;83(2):252-60
2. Reed M, Kerndt C C, Ivabradine Nicolas D, ..
3. Riccioni G, Focus on Ivabradine: a new heart rate-controlling drug.Expert Rev Cardiovasc Ther 2009;7(2):107-20
4. Kim Y, Boucher M, Ottawa AC, ON): Canadian Agency for Drugs and Technologies in Health, CADTH Issues in Emerging Health Technologies..
5. Scicchitano P, Carbonara S, Ricci G, Mandurino C, Locorotondo M, Bulzis G, HCN channels and heart rate.Molecules 2012;17(4):4225-60